Cancer Study Buoys These Small Biotechs

Terns Pharmaceuticals shares jumped as much as 50% on news that cancer cell counts fell over 99% in nearly three-fourths of leukemia patients treated with the firm's once-daily pill.

Barrons • Dec 9, 2025

Why Is Arcellx Stock Surging Today?

Arcellx Inc. (NASDAQ: ACLX) shared new data on Saturday from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel) for relapsed or refractory multiple myeloma (RRMM).

Benzinga • Dec 8, 2025

Arcellx, Inc. (ACLX) Discusses Phase 2 iMMagine-1 Study Results and Multiple Myeloma Treatment Advances Transcript

Arcellx, Inc. (ACLX) Discusses Phase 2 iMMagine-1 Study Results and Multiple Myeloma Treatment Advances Transcript

Seeking Alpha • Dec 7, 2025

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data are being presented during an oral presentation at the 67th American Society o.

Business Wire • Dec 6, 2025

Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will host an Investor Relations event on Saturday, December 6, 2025 at 8:00 p.m. ET. The event will include a panel of clinician experts and a discussion of the latest data from the Company's Phase 2 pivotal iMMagine-1 study in patients wit.

Business Wire • Nov 18, 2025

Arcellx Provides Third Quarter 2025 Financial Results

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Cash, cash equivalents, and marketable securities: As of September 30, 2025, Arcellx had cash, cash equivalents, and marketable securities of $576.0 mi.

Business Wire • Nov 5, 2025

Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates

Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to a loss of $0.48 per share a year ago.

Zacks Investment Research • Nov 5, 2025

Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced it will share two presentations at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 6-9, 2025, in Orlando, Florida, including updated clinical data from iMMagine-1, its Phase 2 pivotal study (publication #25.

Business Wire • Nov 3, 2025

Arcellx, Inc. (ACLX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Arcellx (ACLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 30, 2025

Arcellx, Inc. (ACLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Arcellx, Inc. (NASDAQ:ACLX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Rami Elghandour - Chairman of the Board, CEO & President Christopher Heery - Chief Medical Officer Michelle Gilson - Chief Financial Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst Good afternoon, everyone. Welcome to the session of the Morgan Salary Global Healthcare Conference.

Seeking Alpha • Sep 10, 2025